Clinical trials
HER-2 Positive Breast Cancer clinical trials
Below are recruiting her-2 positive breast cancer clinical trials, each written for real people, not researchers. We’re tracking 253 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06938360Recruiting
Breast-conserving surgery for central breast cancer study
This trial compares breast-conserving surgery (removing only the tumor and nearby tissue) to total mastectomy (removing the whole breast) for women with breast cancer in the central area of the breast. The goal is to see if the less extensive surgery works just as well.
Xi'an, ShaanxiAges 18–70 - NCT07179744Recruiting
Skipping radiation for low-risk node-positive breast cancer
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
Guangzhou, GuangdongAges 18–70 - NCT07182721RecruitingPhase 2
Study of SKB264 plus Inetetamab for advanced HER2+ breast cancer after T-DXd
This trial is testing a combination of two targeted therapies, SKB264 and Inetetamab, for people with advanced HER2-positive breast cancer that has kept growing after treatment with T-DXd and other HER2-targeted therapies. The goal is to see if this new combination can shrink tumors or slow the cancer's growth.
ShanghaiAges 18 years+ - NCT07162675Recruiting
Step count and treatment response in breast cancer patients
This study looks at how your daily step count, measured by a smartwatch, relates to how well your breast cancer responds to treatment before surgery. It may help show if being more active during chemotherapy leads to better outcomes.
Ankara, YenimahalleAges 18 years+ - NCT07150208RecruitingPhase 2
T-DXd with or without Avastin for HER2-low breast cancer that spread to the brain
This trial tests a combination of two targeted drugs (T-DXd and bevacizumab) for people with HER2-low breast cancer that has spread to the brain. It aims to see if adding bevacizumab helps the main drug work better against brain metastases.
ShanghaiAges 18–70 - NCT07140172Recruiting
Radiation or surgery for node-positive breast cancer
This trial compares two treatments for people with breast cancer that has spread to the lymph nodes: radiation therapy to the armpit or surgery to remove the lymph nodes. The goal is to see which approach works best after a tailored surgery to remove the most suspicious lymph nodes.
Bethesda, MarylandAges 18 years+ - NCT07132749Enrolling by invitation
NEPA for nausea prevention during T-DXd in advanced HER2+ or HER2-low breast cancer
This trial tests whether the anti-nausea combination NEPA (netupitant and palonosetron) can prevent nausea and vomiting caused by the targeted therapy T-DXd in people with advanced HER2-positive or HER2-low breast cancer. It may help you if you are about to start T-DXd for the first time and want to manage treatment side effects.
Seoul, Gangnam-guAges 19 years+ - NCT07106632RecruitingPhase 3
Genomic test to guide chemotherapy in young women with breast cancer
This trial uses a genomic test called Prosigna to help decide whether young women with hormone-sensitive breast cancer need chemotherapy after surgery. It aims to avoid unnecessary chemotherapy in those who can safely skip it.
BrusselsAges 35–45 - NCT07053085RecruitingPhase 2
Surgery or radiation for stable HER2+ breast cancer spread
This study tests whether combining surgery or strong focused radiation with standard treatment can help people whose HER2-positive breast cancer has spread to a few spots (5 or fewer) in the body, but not the brain. It's for patients whose cancer is stable after at least 3 months of first-line therapy.
Basking Ridge, New JerseyAges 18 years+ - NCT06677879RecruitingPhase 2
Proton vs photon radiation for left-sided breast cancer
This study is comparing two types of radiation therapy—proton therapy and standard photon therapy—for people with left-sided breast cancer who need radiation after surgery. The goal is to find out which method best protects the heart while effectively treating the cancer.
ShanghaiAges 18–80 - NCT06992882RecruitingPhase 3
Comparing two chemo regimens with Herceptin for early breast cancer
This trial tests if taking oral chemotherapy pills with trastuzumab (Herceptin) works as well as IV chemo (paclitaxel) with Herceptin after surgery for HER2-positive, lymph node-negative early breast cancer. It aims to find a more convenient treatment option.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06954961RecruitingPhase 3
Study of D-0502 for ER+ HER2- advanced breast cancer
This trial tests an oral drug called D-0502 for people with a specific type of advanced breast cancer (ER-positive, HER2-negative). It is for those whose cancer has returned or worsened after hormone therapy, and it may be an option before trying more chemotherapy.
Beijing, Beijing MunicipalityAges 18–75 - NCT06930521Recruiting
Monitoring heart health during HER2 therapy for breast cancer
This study tracks how well the heart handles HER2-targeted therapy (like Herceptin) during the first year of treatment for early-stage breast cancer. It helps keep you safe by checking heart function closely.
Toronto, OntarioAges 18–79 - NCT06914440RecruitingPhase 2
Radiation and immunotherapy before surgery for HR+/HER2- breast cancer
This trial is testing a new treatment approach for patients with a certain type of breast cancer (HR+/HER2-). It combines radiation therapy with chemotherapy and an immunotherapy drug before the patient's main surgery, to see if it can shrink or eliminate the tumor more effectively.
Xi'an, Shannxi ProvinceAges 18–75 - NCT06781281Recruiting
Chemo plus immunotherapy for early HR+/HER2- breast cancer
This trial tests adding an immunotherapy drug (serplulimab) to standard chemotherapy for early-stage HR+/HER2- breast cancer. The goal is to see if the combination works better than chemo alone before surgery.
ZhengzhouAges 18 years+ - NCT06890871Enrolling by invitationPhase 1/Phase 2
Radiation with immunotherapy and anti-angiogenic therapy for advanced HER2-negative breast cancer
This trial tests a combination of radiation therapy, immunotherapy, and a drug that blocks blood vessel growth for advanced HER2-negative breast cancer that has spread. It is for patients whose cancer has worsened after at least two prior treatments.
Wuhan, HubeiAges 18–75 - NCT06885671Recruiting
Shorter vs fewer radiation sessions for breast cancer
This trial compares two types of partial breast radiation: one session versus several shorter sessions. It aims to see if a single treatment is as effective and more convenient for women with early-stage breast cancer.
Prince George, British ColumbiaAges 40 years+ - NCT06686459Recruiting
AI-assisted single-session radiotherapy after breast-conserving surgery
This trial tests a new approach where all radiation is given in one session using AI guidance. It is for women who had breast-conserving surgery with lymph node removal and need radiation afterward.
GuangzhouAges 18–70 - NCT06876714RecruitingPhase 3
Shorter vs Longer HER2 Therapy for Breast Cancer with Complete Response
This trial compares 6 months versus 12 months of HER2-targeted therapy for people with HER2+ breast cancer who had a complete response after chemo and trastuzumab. The goal is to see if a shorter treatment is just as effective.
Phoenix, ArizonaAges 18 years+ - NCT06867484Recruiting
Breast re-irradiation after second lumpectomy
This trial tests whether giving a second round of radiation to the breast after a lumpectomy for a recurrence is safe and effective. It is for people with a specific type of breast cancer (ER+HER2-) who meet strict criteria regarding prior radiation and tumor characteristics.
Boca Raton, FloridaAges 40 years+ - NCT06765590Recruiting
Paclitaxel (albumin-bound) bioequivalence study in breast cancer
This study tests whether a new version of paclitaxel (albumin-bound) works the same as the approved version in people with breast cancer. It's for patients whose cancer has spread or returned after other treatments, or those for whom this drug is recommended by treatment guidelines.
Luoyang, HenanAges 18–75 - NCT06768931RecruitingPhase 2
Combination therapy before surgery for triple-negative breast cancer
This trial tests adding an immunotherapy drug to standard chemotherapy before surgery for triple-negative breast cancer. The goal is to see if this combination works better than chemotherapy alone.
Lanzhou, GansuAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Jonesboro, ArkansasAges 18 years+ - NCT06756932RecruitingPhase 1
Bcl-2 inhibitor combo for advanced HR+ breast cancer
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Iowa City, IowaAges 18 years+
Hear when a new HER-2 Positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her-2 positive breast cancer?
- Yes. Clin2 currently lists 253 recruiting her-2 positive breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her-2 positive breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her-2 positive breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- HR Positive/HER-2 Negative Breast Cancer
- HER2-positive Breast Cancer
- Hormone-receptor-positive Breast Cancer
- ER Positive Breast Cancer
- Estrogen-receptor-positive Breast Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.